CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: A prospective clinical cohort study

John N. Aucott, Mark J. Soloski, Alison W. Rebman, Lauren A. Crowder, Lauren J. Lahey, Catriona A. Wagner, William H. Robinson, Kathleen T. Bechtold

Research output: Contribution to journalArticle

Abstract

Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. Wespeculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.

Original languageEnglish (US)
Pages (from-to)757-766
Number of pages10
JournalClinical and Vaccine Immunology
Volume23
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Lyme Disease
Chemokines
Cohort Studies
Supravalvular Aortic Stenosis
Hypopharyngeal Neoplasms
Chemokine CCL19
Immunologic Factors
Lymphoid Tissue
Erythema
Microarray Analysis
ROC Curve
Biological Markers
Cytokines
Physicians
T-Lymphocytes
Health
Infection
Library Catalogs
Aortic Valve Prolapse
Hexosaminidase A

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome : A prospective clinical cohort study. / Aucott, John N.; Soloski, Mark J.; Rebman, Alison W.; Crowder, Lauren A.; Lahey, Lauren J.; Wagner, Catriona A.; Robinson, William H.; Bechtold, Kathleen T.

In: Clinical and Vaccine Immunology, Vol. 23, No. 9, 01.09.2016, p. 757-766.

Research output: Contribution to journalArticle

Aucott, John N.; Soloski, Mark J.; Rebman, Alison W.; Crowder, Lauren A.; Lahey, Lauren J.; Wagner, Catriona A.; Robinson, William H.; Bechtold, Kathleen T. / CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome : A prospective clinical cohort study.

In: Clinical and Vaccine Immunology, Vol. 23, No. 9, 01.09.2016, p. 757-766.

Research output: Contribution to journalArticle

@article{9c6b30b815464867933815a4a8af47b2,
title = "CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome: A prospective clinical cohort study",
abstract = "Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. Wespeculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.",
author = "Aucott, {John N.} and Soloski, {Mark J.} and Rebman, {Alison W.} and Crowder, {Lauren A.} and Lahey, {Lauren J.} and Wagner, {Catriona A.} and Robinson, {William H.} and Bechtold, {Kathleen T.}",
year = "2016",
month = "9",
doi = "10.1128/CVI.00071-16",
volume = "23",
pages = "757--766",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - CCL19 as a chemokine risk factor for posttreatment lyme disease syndrome

T2 - Clinical and Vaccine Immunology

AU - Aucott,John N.

AU - Soloski,Mark J.

AU - Rebman,Alison W.

AU - Crowder,Lauren A.

AU - Lahey,Lauren J.

AU - Wagner,Catriona A.

AU - Robinson,William H.

AU - Bechtold,Kathleen T.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. Wespeculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.

AB - Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. Wespeculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.

UR - http://www.scopus.com/inward/record.url?scp=84987638671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987638671&partnerID=8YFLogxK

U2 - 10.1128/CVI.00071-16

DO - 10.1128/CVI.00071-16

M3 - Article

VL - 23

SP - 757

EP - 766

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 9

ER -